DE69920473D1 - Neue fluoreszensfarbstoffe und ihre anwendung in fluoreszensnachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung - Google Patents

Neue fluoreszensfarbstoffe und ihre anwendung in fluoreszensnachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung

Info

Publication number
DE69920473D1
DE69920473D1 DE69920473T DE69920473T DE69920473D1 DE 69920473 D1 DE69920473 D1 DE 69920473D1 DE 69920473 T DE69920473 T DE 69920473T DE 69920473 T DE69920473 T DE 69920473T DE 69920473 D1 DE69920473 D1 DE 69920473D1
Authority
DE
Germany
Prior art keywords
protease
whole cells
caspases
fluorescent
reporter molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69920473T
Other languages
English (en)
Other versions
DE69920473T2 (de
Inventor
Han-Zhong Zhang
Xiong Cai
A Drewe
Wu Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytovia Therapeutics LLC
Original Assignee
Cytovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovia Inc filed Critical Cytovia Inc
Application granted granted Critical
Publication of DE69920473D1 publication Critical patent/DE69920473D1/de
Publication of DE69920473T2 publication Critical patent/DE69920473T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69920473T 1998-07-21 1999-07-21 Neue fluoreszenzfarbstoffe und ihre anwendung in fluoreszenznachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung Expired - Fee Related DE69920473T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9364298P 1998-07-21 1998-07-21
US93642P 1998-07-21
PCT/US1999/016423 WO2000004914A1 (en) 1998-07-21 1999-07-21 Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof

Publications (2)

Publication Number Publication Date
DE69920473D1 true DE69920473D1 (de) 2004-10-28
DE69920473T2 DE69920473T2 (de) 2006-02-23

Family

ID=22240008

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920473T Expired - Fee Related DE69920473T2 (de) 1998-07-21 1999-07-21 Neue fluoreszenzfarbstoffe und ihre anwendung in fluoreszenznachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung

Country Status (6)

Country Link
US (2) US6248904B1 (de)
EP (1) EP1100520B1 (de)
AT (1) ATE276754T1 (de)
AU (1) AU5116099A (de)
DE (1) DE69920473T2 (de)
WO (1) WO2000004914A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517781B1 (en) * 1997-06-02 2003-02-11 Aurora Biosciences Corporation Low fluorescence assay platforms and related methods for drug discovery
PL341661A1 (en) * 1997-10-10 2001-04-23 Cytovia Novel fluorescent reporter particles and their application in combination with testing capsizes
US6342611B1 (en) 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
DE69920473T2 (de) * 1998-07-21 2006-02-23 Cytovia, Inc., San Diego Neue fluoreszenzfarbstoffe und ihre anwendung in fluoreszenznachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
US6391575B1 (en) 1999-03-05 2002-05-21 Idun Pharmaceuticals, Inc. Methods for detecting membrane derived caspase activity and modulators thereof
US6524797B1 (en) * 1999-05-10 2003-02-25 Bernhard O. Palsson Methods of identifying therapeutic compounds in a genetically defined setting
JP2003508080A (ja) * 1999-09-10 2003-03-04 オンコイミューニン，インコーポレイティド 生物学的サンプル中のプロテアーゼの検出のための組成物及びその使用方法
US20040121941A1 (en) * 1999-09-28 2004-06-24 Burm Brigitte Elisa Anna Novel inhibitors of prenylated pyrophosphate consuming enzymes
TW200628612A (en) * 2000-07-19 2006-08-16 Pharmacia & Up John Company Substrates and assays for β-secretase activity
AU2001278135A1 (en) 2000-08-03 2002-02-18 Cytovia, Inc. Method of identifying immunosuppressive agents
US7083945B1 (en) * 2000-10-27 2006-08-01 The Board Of Regents Of The University Of Texas System Isolation of binding proteins with high affinity to ligands
US6979530B2 (en) * 2001-05-21 2005-12-27 Applera Corporation Peptide conjugates and fluorescence detection methods for intracellular caspase assay
CA2454419A1 (en) * 2001-07-20 2003-01-30 Children's Medical Center Corporation Invasion complex and methods of targeting
US7291698B2 (en) * 2001-09-04 2007-11-06 Stephen Eliot Zweig Synthetic substrate for high specificity enzymatic assays
US7026111B2 (en) * 2001-10-15 2006-04-11 Beckman Coulter, Inc. Methods and reagents for improved cell-based assays
WO2003061711A2 (en) * 2002-01-16 2003-07-31 Visen Medical, Inc. Chromophore probes for optical imaging
US7927871B2 (en) * 2002-01-29 2011-04-19 Oncoimmunin, Inc. Visualization and quantitation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
US7393835B2 (en) 2002-04-22 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of protein kinase C
US6933275B2 (en) 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
EP1517997A4 (de) * 2002-05-24 2006-11-15 Molecular Devices Corp Luminogene proteasesubstrate
CA2490961A1 (en) * 2002-07-01 2004-01-08 Guava Technologies, Inc. Fluorescent dyes, energy transfer couples and methods
US7118877B2 (en) 2002-07-08 2006-10-10 Wyeth Caspase 9 activation and uses therefor
US7195884B2 (en) * 2002-07-19 2007-03-27 Promega Corp. Methods and kits for transferases
US6821744B2 (en) 2002-10-29 2004-11-23 Roche Diagnostics Operations, Inc. Method, assay, and kit for quantifying HIV protease inhibitors
CA2523517C (en) * 2003-04-25 2013-07-30 Dana-Farber Cancer Institute, Inc. Bcl2l12 polypeptide activators and inhibitors
US7504382B2 (en) * 2003-05-06 2009-03-17 Cytovia, Inc. Protease inhibitors for coronaviruses and SARS-CoV and the use thereof
AU2003241559A1 (en) * 2003-05-16 2004-12-13 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase c peptides for use in withdrawal
EP1598428A1 (de) 2004-05-18 2005-11-23 Georg Dewald Verfahren und Kits zum Nachweis von erblichen angioedema typ III
CA2589460A1 (en) * 2004-11-24 2006-06-01 Theraptosis S.A. New peptides useful as dual caspase-2/-6 inhibitors and their biological applications
CN101296927A (zh) 2005-09-02 2008-10-29 Visen医药公司 生物相容的含n,n-二取代磺酰胺的荧光染料标记
DK1937676T3 (en) * 2005-09-02 2017-03-06 Visen Medical Inc Biocompatible fluorescent imaging compounds
WO2007028118A2 (en) 2005-09-02 2007-03-08 Visen Medical, Inc. Nicotinic acid and picolinic acid derived near-infrared fluorophores
US7452973B2 (en) * 2005-11-07 2008-11-18 Wisconsin Alumni Research Foundation Cell-permeable fluorescent proteins
WO2007065080A2 (en) * 2005-11-29 2007-06-07 University Of Maryland, College Park Control of apoptosis by controlling the propensity of ceramide channel formation
KR100909996B1 (ko) 2007-09-19 2009-07-29 한국생명공학연구원 카스파제-3(ｃａｓｐａｓｅ-3)의 활성 검출용 융합 단백질및 이를 이용한 카스파제-3의 활성 검출방법
US8679836B2 (en) * 2007-10-01 2014-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of monitoring angiogenesis and metastasis in three dimensional co-cultures
US20090088341A1 (en) * 2007-10-01 2009-04-02 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Multiplex assay method for mixed cell populations
WO2009061905A1 (en) * 2007-11-09 2009-05-14 Genzyme Corporation Methods of measuring cell viability without using control cells
WO2012061732A1 (en) 2010-11-05 2012-05-10 Cell Signaling Technology, Inc. Motif-specific and context-independent antibodies to a cleaved caspase motif or a sumoylated lysine-containing motif
RU2482128C1 (ru) * 2011-12-28 2013-05-20 Замертон Холдингс Лимитед Пептиды, обладающие цитопротекторной активностью
JP6962684B2 (ja) * 2013-07-18 2021-11-05 セーホーエル．ハンセン アクティーゼルスカブ 乳凝固アスパラギン酸プロテアーゼ酵素組成物
EP3033087A4 (de) 2013-08-16 2017-03-15 The J. David Gladstone Institutes Zusammensetzungen und verfahre zur identifizierung von latent infizierten zellen
WO2019117812A1 (en) * 2017-12-12 2019-06-20 Nanyang Technological University Near infra-red molecular probes for use in diagnosis of fibrotic conditions and screening of anti-fibrotic drugs
KR102186097B1 (ko) * 2017-12-26 2020-12-03 주식회사 엘지화학 잔텐계 화합물 및 이를 포함하는 감광성 수지 조성물
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US4336186A (en) 1978-08-03 1982-06-22 Gargiulo Robert J Analytical fluorogenic substrates for proteolytic enzymes
US4500471A (en) 1980-04-16 1985-02-19 Occidental Chemical Corporation Preparation of trifluoromethyl-benzoyl halides
JPS588769A (ja) 1981-07-08 1983-01-18 Ricoh Co Ltd インクジエツト記録用インク組成物
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4640893A (en) 1983-10-28 1987-02-03 University Of Illinois Novel rhodamine derivatives as fluorogenic substrates for proteinases
US4557862A (en) * 1983-10-28 1985-12-10 University Patents, Inc. Rhodamine derivatives as fluorogenic substrates for proteinases
DE3531272C2 (de) 1985-09-02 1997-09-25 Basf Ag Verfahren zur Herstellung von veresterten Rhodamin-Farbstoffen
US4900686A (en) 1987-04-02 1990-02-13 Polaroid Corporation Fluorescent conjugates and biological diagnostic assay
DE3916729A1 (de) 1989-05-23 1990-12-06 Behringwerke Ag Fluorogene verbindungen und ihre verwendung
US5587490A (en) 1990-04-16 1996-12-24 Credit Managers Association Of California Method of inactivation of viral and bacterial blood contaminants
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
US5208148A (en) 1990-12-07 1993-05-04 Molecular Probes, Inc. Lipophilic fluorescent glycosidase substrates
EP0591275B1 (de) 1991-06-24 1999-03-31 Zeneca Limited Verwendung von 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandion zur behandlung von tyrosinämie sowie pharmazeutische zusammensetzungen
US6348570B1 (en) 1991-08-16 2002-02-19 Merck & Co., Inc. Chromophore containing compounds and their use in determining interleukin-1β convertase activity
EP0603266B1 (de) 1991-08-23 1999-05-12 Molecular Probes, Inc. Verwendung von haloalkylderivaten von reportermolekülen zur analyse der metabolischen aktivität in zellen
US5576424A (en) 1991-08-23 1996-11-19 Molecular Probes, Inc. Haloalkyl derivatives of reporter molecules used to analyze metabolic activity in cells
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
AU3129493A (en) 1991-11-12 1993-06-15 Promega Corporation Non-radioactive enzyme assay
WO1994006906A1 (en) 1992-09-18 1994-03-31 Merck & Co., Inc. DNA ENCODING MURINE PRECURSOR INTERLEUKIN 1β CONVERTING ENZYME
EP0623599A1 (de) 1993-03-26 1994-11-09 Ciba-Geigy Ag Optischer Sensor zur Bestimmung von Kationen
US6087160A (en) 1993-06-24 2000-07-11 The General Hospital Corporation Programmed cell death genes and proteins
US5659024A (en) 1994-01-14 1997-08-19 The Burnham Institute Promotors that regulate the expression of genes involved in cell death
US5556992A (en) 1994-09-02 1996-09-17 Universite De Montreal Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias
US5605809A (en) 1994-10-28 1997-02-25 Oncoimmunin, Inc. Compositions for the detection of proteases in biological samples and methods of use thereof
US5843635A (en) 1995-02-27 1998-12-01 Dana-Farber Cancer Institute, Inc. Inhibition of APC-mediated apoptosis of activated T lymphocytes
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
US5698411A (en) 1995-05-18 1997-12-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5776720A (en) 1995-05-18 1998-07-07 Coulter Corporation Assay reagent
US5733719A (en) 1995-05-18 1998-03-31 Coulter Corporation Method of making an assay compound
US5871946A (en) 1995-05-18 1999-02-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
WO1996036729A1 (en) 1995-05-18 1996-11-21 Coulter International Corp. An assay reagent and a method of making and using the assay reagent
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
US5834216A (en) 1995-09-06 1998-11-10 Arch Development Corporation Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis)
WO1997011067A1 (en) 1995-09-21 1997-03-27 Novartis Ag Polymer-bound fluorophores as optical ion sensors
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
DE19639450A1 (de) 1996-09-25 1998-04-09 Deutsches Krebsforsch Verfahren zum diagnostischen Nachweis von Apoptose in Zellen
US5897992A (en) 1996-09-27 1999-04-27 Cold Spring Harbor Laboratory Cell-free assay using oncogene-induced apoptosis in drug-resistant cells
US5773236A (en) * 1997-04-25 1998-06-30 Molecule Probes, Inc. Assay for glutathiane transferase using polyhaloaryl-substituted reporter molecules
US6270980B1 (en) 1997-06-05 2001-08-07 Idun Pharmaceuticals, Inc. Rapid methods for identifying modifiers of cellular apoptosis activity
WO1998057664A1 (en) 1997-06-19 1998-12-23 The General Hospital Corporation Interleukin converting enzyme (ice) and central nervous system damage
US6342611B1 (en) 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
PL341661A1 (en) 1997-10-10 2001-04-23 Cytovia Novel fluorescent reporter particles and their application in combination with testing capsizes
CN1297354A (zh) 1998-03-16 2001-05-30 西托维亚公司 二肽卡斯帕酶抑制剂及其用途
DE69920473T2 (de) 1998-07-21 2006-02-23 Cytovia, Inc., San Diego Neue fluoreszenzfarbstoffe und ihre anwendung in fluoreszenznachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
AU2864100A (en) 1999-02-01 2000-08-18 Cytovia, Inc. Methods of identifying therapeutically effective antineoplastic agents with cultured cells having intact cell membranes and corresponding products
ATE336480T1 (de) 1999-03-16 2006-09-15 Cytovia Inc Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
WO2000061542A1 (en) 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
US6462041B1 (en) 1999-05-21 2002-10-08 Cytovia, Inc. Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
IL148426A0 (en) 1999-08-27 2002-09-12 Cytovia Inc α-HYDROXY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death

Also Published As

Publication number Publication date
US6248904B1 (en) 2001-06-19
AU5116099A (en) 2000-02-14
DE69920473T2 (de) 2006-02-23
EP1100520A4 (de) 2002-07-17
EP1100520B1 (de) 2004-09-22
US6984718B2 (en) 2006-01-10
US20030208037A1 (en) 2003-11-06
WO2000004914A1 (en) 2000-02-03
EP1100520A1 (de) 2001-05-23
ATE276754T1 (de) 2004-10-15

Similar Documents

Publication Publication Date Title
ATE276754T1 (de) Neue fluoreszensfarbstoffe und ihre anwendung in fluoreszensnachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
HUP0100079A2 (hu) Új, fluoreszcens riportermolekulák és alkalmazásaik, többek között kaszpázok vizsgálatára
McStay et al. Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways
Wilkesman et al. Protease analysis by zymography: a review on techniques and patents
Sapojnikova et al. Correlation between MMP-9 and extracellular cytokine HMGB1 in prediction of human ischemic stroke outcome
Hanspal et al. Detection of protease inhibitors using substrate-containing sodium dodecyl sulfate-polyacrylamide gel electrophoresis
DE60238132D1 (de) Patientenklassifizierung
ATE345399T1 (de) Biomarker und targets für die diagnose, prognose und behandlung von prostat krankheiten
Capone et al. Characterization of metalloproteinases, oxidative status and inflammation levels in the different stages of fibrosis in HCV patients
Strucksberg et al. Proteasomal activity in skeletal muscle: a matter of assay design, muscle type, and age
WO2002063271A8 (en) Activity based probe analysis
Fujihara et al. Circulating cell-free DNA fragment analysis by microchip electrophoresis and its relationship with DNase I in cardiac diseases
US7026111B2 (en) Methods and reagents for improved cell-based assays
EP0489839A4 (en) Novel hydrolytic enzyme inhibitors and substrates and assays, methods and kits embodying same
WO2004033397A3 (en) Activity-based probes, and methods of their preparation and use
Koster et al. The use of leucocytes as an aid in the diagnosis of a variant of glycogen storage disease type II (Pompe's disease)
EP1774327B1 (de) Verfahren und kits zur messung von adamts13/fxi-komplexen
EP4373961A1 (de) Verwendung von genetischen und epigenetischen markern zum nachweis des zelltodes
JP6360848B2 (ja) ライソゾーム病３疾患責任酵素の迅速マススクリーニング検査法
Ganesh et al. Flow cytometric determination of aminopeptidase activities in viable cells using fluorogenic rhodamine 110 substrates
FR2875242B1 (fr) Nouveaux substrats enzymatiques derives de phenoxazinone et leur utilisation comme revelateur dans la detection de microorganismes a activite peptidase
RU2528100C1 (ru) Способ прогнозирования развития гематогенных метастазов после комбинированного лечения рака почки
Durdey et al. The role of peptidases in cancer of the rectum and sigmoid colon
Radulescu et al. Biomarkers of oxidative stress, proliferation, inflammation and invasivity in saliva from oral cancer patients
DE50212719D1 (de) Testsystem zur Bestimmung von in-vivo aktiven Proteasen der Hämostase in biologischen Flüssigkeiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee